Robert B Schonberger1, Todd Gilbertsen2, Feng Dai2. 1. Department of Anesthesiology, Yale University School of Medicine, New Haven, CT. Electronic address: Robert.schonberger@yale.edu. 2. Department of Anesthesiology, Yale University School of Medicine, New Haven, CT.
Abstract
OBJECTIVE(S): Observational database research frequently relies on imperfect administrative markers to determine comorbid status, and it is difficult to infer to what extent the associated misclassification impacts validity in multivariable analyses. The effect that imperfect markers of disease will have on validity in situations in which researchers attempt to match populations that have strong baseline health differences is underemphasized as a limitation in some otherwise high-quality observational studies. The present simulations were designed as a quantitative demonstration of the importance of this common and underappreciated issue. DESIGN: Two groups of Monte Carlo simulations were performed. The first demonstrated the degree to which controlling for a series of imperfect markers of disease between different populations taking 2 hypothetically harmless drugs would lead to spurious associations between drug assignment and mortality. The second Monte Carlo simulation applied this principle to a recent study in the field of anesthesiology that purported to show increased perioperative mortality in patients taking metoprolol versus atenolol. SETTING/PARTICIPANTS/ INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Simulation 1: High type-1 error (ie, false positive findings of an independent association between drug assignment and mortality) was observed as sensitivity and specificity declined and as systematic differences in disease prevalence increased. Simulation 2: Propensity score matching across several imperfect markers was unlikely to eliminate important baseline health disparities in the referenced study. CONCLUSIONS: In situations in which large baseline health disparities exist between populations, matching on imperfect markers of disease may result in strong bias away from the null hypothesis.
OBJECTIVE(S): Observational database research frequently relies on imperfect administrative markers to determine comorbid status, and it is difficult to infer to what extent the associated misclassification impacts validity in multivariable analyses. The effect that imperfect markers of disease will have on validity in situations in which researchers attempt to match populations that have strong baseline health differences is underemphasized as a limitation in some otherwise high-quality observational studies. The present simulations were designed as a quantitative demonstration of the importance of this common and underappreciated issue. DESIGN: Two groups of Monte Carlo simulations were performed. The first demonstrated the degree to which controlling for a series of imperfect markers of disease between different populations taking 2 hypothetically harmless drugs would lead to spurious associations between drug assignment and mortality. The second Monte Carlo simulation applied this principle to a recent study in the field of anesthesiology that purported to show increased perioperative mortality in patients taking metoprolol versus atenolol. SETTING/PARTICIPANTS/ INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Simulation 1: High type-1 error (ie, false positive findings of an independent association between drug assignment and mortality) was observed as sensitivity and specificity declined and as systematic differences in disease prevalence increased. Simulation 2: Propensity score matching across several imperfect markers was unlikely to eliminate important baseline health disparities in the referenced study. CONCLUSIONS: In situations in which large baseline health disparities exist between populations, matching on imperfect markers of disease may result in strong bias away from the null hypothesis.
Authors: Herbert C Szeto; Robert K Coleman; Parisa Gholami; Brian B Hoffman; Mary K Goldstein Journal: Am J Manag Care Date: 2002-01 Impact factor: 2.229
Authors: Amy C Justice; Elaine Lasky; Kathleen A McGinnis; Melissa Skanderson; Joseph Conigliaro; Shawn L Fultz; Kristina Crothers; Linda Rabeneck; Maria Rodriguez-Barradas; Sharon B Weissman; Kendall Bryant Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Kristina Crothers; Joseph L Goulet; Maria C Rodriguez-Barradas; Cynthia L Gibert; Adeel A Butt; R Scott Braithwaite; Robin Peck; Amy C Justice Journal: J Gen Intern Med Date: 2007-03-01 Impact factor: 5.128
Authors: Murtuza F Bharmal; Michael Weiner; Laura P Sands; Huiping Xu; Bruce A Craig; Joseph Thomas Journal: Alzheimer Dis Assoc Disord Date: 2007 Apr-Jun Impact factor: 2.703
Authors: Eric Y Chen; George Michel; Bin Zhou; Feng Dai; Shamsuddin Akhtar; Robert B Schonberger Journal: Drugs Aging Date: 2020-06 Impact factor: 3.923
Authors: Rishi J Desai; Daniel H Solomon; Nancy Shadick; Christine Iannaccone; Seoyoung C Kim Journal: Pharmacoepidemiol Drug Saf Date: 2016-01-13 Impact factor: 2.890
Authors: Robert B Schonberger; Antonio Gonzalez-Fiol; Kristen L Fardelmann; Amit Bardia; George Michel; Feng Dai; Trevor Banack; Aymen Alian Journal: Blood Press Monit Date: 2021-02-01 Impact factor: 1.444
Authors: Robert B Schonberger; Vivek Vallurupalli; Hollie Matlin; Daina Blitz; Adambeke Nwozuzu; Brian Barron; Yuemei Zhang; Feng Dai; Daniel Jacoby; Khurram Nasir; Amit Bardia Journal: Prev Med Rep Date: 2020-04-08